Use of dapagliflozin as an add-on to insulin therapy in patients with suboptimally controlled type 2 diabetes

被引：2
|
作者：
Das, Gautam [1 ]
Surya, Ashutosh [1 ]
Abusahmin, Hussam [1 ]
机构：
[1] Cwm Taf Univ Hlth Board, Dept Endocrinol, Prince Charles Hosp, Merthyr Tydfil CF47 9DT, M Glam, Wales
来源：
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM | 2018年 / 9卷 / 08期
关键词：
RANDOMIZED-TRIAL; EFFICACY; SENSITIVITY; INHIBITOR; SECRETION; MELLITUS; WEIGHT; SAFETY;
D O I：
10.1177/2042018818771434
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：269 / 270
页数：2
相关论文
共 50 条
  • [1] Dapagliflozin as Add-On Therapy in Asian Patients with Type 2 Diabetes Inadequately Controlled on Insulin
    Yang, Wenying
    Ma, Jianhua
    Li, Yiming
    Li, Yanbing
    Zhou, Zhiguang
    Kim, Jae Hyeon
    Zhao, June
    Ptaszynska, Agata
    DIABETES, 2017, 66 : A338 - A338
  • [2] Real-World Use of Dapagliflozin as Add-On to Insulin Therapy in Patients with Type 2 Diabetes
    Spaic, Tamara
    Harris, Stewart B.
    Mequanint, Selam
    Reichert, Sonja
    Miller, Kristina
    DIABETES, 2017, 66 : A327 - A328
  • [3] Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
    Rosenstock, Julio
    Mathieu, Chantal
    Chen, Hungta
    Garcia-Sanchez, Ricardo
    Saraiva, Gabriela Luporini
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2018, 62 (04): : 424 - 430
  • [4] Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
    von Websky, Karoline
    Reichetzeder, Christoph
    Hocher, Berthold
    VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 : 681 - 694
  • [5] Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial
    Yang, Wenying
    Ma, Jianhua
    Li, Yiming
    Li, Yanbing
    Zhou, Zhiguang
    Kim, Jae Hyeon
    Zhao, June
    Ptaszynska, Agata
    JOURNAL OF DIABETES, 2018, 10 (07) : 589 - 599
  • [6] Dapagliflozin plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type 2 Diabetes
    Frias, Juan P.
    Gonzalez-Galvez, Guillermo
    Johnsson, Eva K.
    Maaske, Jill
    Peters, Anne
    DIABETES, 2018, 67
  • [7] Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial
    Araki, Eiichi
    Onishi, Yukiko
    Asano, Michiko
    Kim, Hyosung
    Yajima, Toshitaka
    DIABETES OBESITY & METABOLISM, 2017, 19 (04): : 562 - 570
  • [8] Real-World Use of Canagliflozin as Add-On to Insulin Therapy in Patients with Type 2 Diabetes
    Harris, Stewart B.
    Reichert, Sonja
    Mequanint, Selam M.
    Spaic, Tamara
    Esler, Jim
    DIABETES, 2017, 66 : A328 - A329
  • [9] Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study
    Shin, Yujin
    Choi, Haeri
    Lim, Soo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 175
  • [10] Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study
    Han, Kyung Ah
    Hwang, You-Cheol
    Moon, Shin Je
    Cho, Ho Chan
    Yoo, Hye Jin
    Choi, Sung Hee
    Chon, Suk
    Kim, Kyoung-Ah
    Kim, Tae Nyun
    Kang, Jun Goo
    Park, Cheol-Young
    Won, Jong Chul
    Cho, Eunjoo
    Kim, Jeongyun
    Park, Kyong Soo
    DIABETES OBESITY & METABOLISM, 2024, 26 (09): : 3743 - 3752
12345